Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: A historical perspective and the eastern cooperative oncology group experience

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 133S-137S

  Johnson, David H ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Carboplatin; Cisplatin; Combination chemotherapy; Non small cell lung cancer; Performance status; Survival

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IPROPLATIN; MITOMYCIN; VINBLASTINE;

CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED STATES;

EID: 0033996533     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia, PA: Lippincott-Raven, 1997:858-910
2. Perez CA, Stanley K, Rubin P, et al. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1980; 6:987-994
3. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327:1434-1441
4. Ihde DC, Minna JD. Non-small cell lung cancer: part II. Treatment. Curr Probl Cancer 1991; 15:109-154
5. Johnson DH. Chemotherapy for unresectable non-small cell lung cancer. Semin Oncol 1990; 17:20-29
6. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95:414-420
7. Kris MG, Gralla RJ, Kalman LA, et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985; 69:387-395
8. Ruckdeschel JC, Mehta CR, Salazar OM, et al. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II. Cancer Treat Rep 1981; 65:965-967
9. Ruckdeschel JC, Day R, Weissman CH, et al. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV). Cancer Treat Rep 1984; 68:1325-1329
10. Ruckdeschel JC, Finkelstein DM, Mason BA, et al. Chemotherapy for metastatic non-small cell lung carcinoma: EST 2575, generation V: a randomized comparison of four cisplatin-containing regimens. J Clin Oncol 1985; 3:72-79
11. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4:14-22
12. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7:1602-1613
13. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4:702-709
14. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25-32
15. Rapp E, Pater JL, Willen A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641
16. Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: does chemotherapy make a difference? Cancer 1989; 63:1271-1278
17. Woods RL, Williams CJ, Levi J, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 66:608-611
18. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991; 9:1453-1461
19. Kaasa S, Lund E, Thorud E, et al. Symptomatic treatment versus combination chemotherapy in patients with extensive non-small cell lung cancer. Cancer 1991; 67:2443-2447
20. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:794-800
21. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909
22. LeChevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-367
23. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Group (ECOG) trial [abstract 1145]. Proc Am Soc Clin Oncol 1996; 15:382
24. Perez E, Putney JD, Gandara D. In vitro dose-response relationship to cisplatin in human non-small cell lung cancer cell lines [abstract]. Proc Am Assoc Cancer Res 1989; 30:459
25. Klastersky J, Sculier JP, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 1986; 4:1780-1786
26. Shinkai T, Saijo N, Eguchi K, et al. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986; 77:782-789
27. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11:873-878
28. Bunn PA Jr. Clinical experiences with carboplatin (Paraplatin®) in lung cancer. Semin Oncol 1992; 19(1suppl2):1-11
29. Bunn PA Jr. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol 1996; 23(6suppl16):18-25
30. Bonomi P. Carboplatin in non-small cell lung cancer: review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials. Semin Oncol 1991; 18(suppl 2):2-7
31. Kramer BS, Birch R, Greco A, et al. Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. Am J Clin Oncol 1988; 11:643-645
32. Kreisman H, Ginsberg S, Propert KJ, et al. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 1987; 71:1049-1052
33. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 1993; 11:598-606
34. Gandara DR, Wold H, Perez EA, et al. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989; 81:790-794
35. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308) [abstract 1110]. Proc Am Soc Clin Oncol 1996; 15:374
36. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7:1087-1092
37. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748-1756
38. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 1990; 8:1556-1562
39. 2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous c-cell bronchogenic carcinoma: a randomized phase III study in 221 patients [abstract 45]. Lung Cancer 1997; 18(suppl1):14-15
40. Giaccone G, Postmus P, Debruyne C, et al. Final results of an EORTC phase III study of paclitaxel versus teniposide in combination with cisplatin in advanced NSCLC [abstract 1653]. Proc Am Soc Clin Oncol 1997; 16:460A
41. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71:366-370
42. Tummarello D, Graziano F, Isidori P, et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995; 35:249-253
43. Thatcher N, Anderson H, Betticher DC, et al. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anti-Cancer Drugs 1995; 6(suppl6):39-48
44. Thatcher N, Hopwood P, Anderson H. Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 1997; 33(suppl1): S8-S13
45. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4:1604-1614
46. Buccheri GF, Ferrigno D, Curcio A, et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 1989; 63:428-432
47. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997; 15:2996-3018
48. Evans WK, Will BP, Berthelot JM, et al. The cost of managing lung cancer in Canada. Oncology 1995; 9(11suppl): 147-153
49. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300:1458-1460
50. Douglas IS, White SR. Should non-small cell carcinoma of the lung be treated with chemotherapy? Con: therapeutic empiricism; the case against chemotherapy in non-small cell lung cancer. Am J Respir Crit Care Med 1995; 151:1288-1291
51. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer J Clin Oncol 1995; 13:1904-1911